JP2003508353A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2003508353A5 JP2003508353A5 JP2001512520A JP2001512520A JP2003508353A5 JP 2003508353 A5 JP2003508353 A5 JP 2003508353A5 JP 2001512520 A JP2001512520 A JP 2001512520A JP 2001512520 A JP2001512520 A JP 2001512520A JP 2003508353 A5 JP2003508353 A5 JP 2003508353A5
- Authority
- JP
- Japan
- Prior art keywords
- ylmethyl
- thiophen
- chloro
- amino
- quinazolin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- -1 acetylamino, propanoylamino, 2-methylpropanoylamino, butanoylamino Chemical group 0.000 description 15
- 150000001875 compounds Chemical class 0.000 description 4
- 125000000217 alkyl group Chemical group 0.000 description 3
- 125000004442 acylamino group Chemical group 0.000 description 2
- 125000003545 alkoxy group Chemical group 0.000 description 2
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 description 2
- 125000003118 aryl group Chemical group 0.000 description 2
- 125000003739 carbamimidoyl group Chemical group C(N)(=N)* 0.000 description 2
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 125000005843 halogen group Chemical group 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- GTCAXTIRRLKXRU-UHFFFAOYSA-N methyl carbamate Chemical compound COC(N)=O GTCAXTIRRLKXRU-UHFFFAOYSA-N 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 125000001624 naphthyl group Chemical group 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- MYYBQVGASMWCLE-GXKRWWSZSA-N (3s)-1-[(4-aminoquinazolin-7-yl)methyl]-4-[[3-(5-chlorothiophen-2-yl)-1h-pyrazol-5-yl]methyl]-3-methylpiperazin-2-one;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F.N1([C@H](C(N(CC=2C=C3N=CN=C(N)C3=CC=2)CC1)=O)C)CC(NN=1)=CC=1C1=CC=C(Cl)S1 MYYBQVGASMWCLE-GXKRWWSZSA-N 0.000 description 1
- ILROOURZVRAYGD-GXKRWWSZSA-N (3s)-1-[(4-aminoquinazolin-7-yl)methyl]-4-[[5-(5-chlorothiophen-2-yl)-1,2-oxazol-3-yl]methyl]-3-methylpiperazin-2-one;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F.N1([C@H](C(N(CC=2C=C3N=CN=C(N)C3=CC=2)CC1)=O)C)CC(=NO1)C=C1C1=CC=C(Cl)S1 ILROOURZVRAYGD-GXKRWWSZSA-N 0.000 description 1
- DRGIGDYIMYVIPD-TXEPZDRESA-N (3s)-1-[(4-aminoquinazolin-7-yl)methyl]-4-[[5-(5-chlorothiophen-2-yl)-1,2-oxazol-3-yl]methyl]-3-propylpiperazin-2-one;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F.N1([C@H](C(N(CC=2C=C3N=CN=C(N)C3=CC=2)CC1)=O)CCC)CC(=NO1)C=C1C1=CC=C(Cl)S1 DRGIGDYIMYVIPD-TXEPZDRESA-N 0.000 description 1
- ULIIZNSKJMOVMX-UHFFFAOYSA-N 1,2-oxazole;thiophene Chemical compound C=1C=CSC=1.C=1C=NOC=1 ULIIZNSKJMOVMX-UHFFFAOYSA-N 0.000 description 1
- CIRUOCWGWWYEOA-UHFFFAOYSA-N 1-[(4-aminoquinazolin-7-yl)methyl]-4-[[3-(5-chlorothiophen-2-yl)-1,2-oxazol-5-yl]methyl]piperazin-2-one;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F.C=1C=C2C(N)=NC=NC2=CC=1CN(C(C1)=O)CCN1CC(ON=1)=CC=1C1=CC=C(Cl)S1 CIRUOCWGWWYEOA-UHFFFAOYSA-N 0.000 description 1
- SSMRLXKJFFIPLJ-UHFFFAOYSA-N 1-[(4-aminoquinazolin-7-yl)methyl]-4-[[3-(5-chlorothiophen-2-yl)-1h-pyrazol-5-yl]methyl]piperazin-2-one;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F.C=1C=C2C(N)=NC=NC2=CC=1CN(C(C1)=O)CCN1CC(NN=1)=CC=1C1=CC=C(Cl)S1 SSMRLXKJFFIPLJ-UHFFFAOYSA-N 0.000 description 1
- TZASSKUFFUBNAV-UHFFFAOYSA-N 1-[(4-aminoquinazolin-7-yl)methyl]-4-[[5-(5-chlorothiophen-2-yl)-1,2-oxazol-3-yl]methyl]piperazin-2-one;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F.C=1C=C2C(N)=NC=NC2=CC=1CN(C(C1)=O)CCN1CC(=NO1)C=C1C1=CC=C(Cl)S1 TZASSKUFFUBNAV-UHFFFAOYSA-N 0.000 description 1
- MTWHDIHXYWJEFH-UHFFFAOYSA-N 1-[(4-aminoquinazolin-7-yl)methyl]-4-[[5-(5-chlorothiophen-2-yl)-1,3,4-thiadiazol-2-yl]methyl]piperazin-2-one Chemical compound C1CN(C(=O)CN1CC2=NN=C(S2)C3=CC=C(S3)Cl)CC4=CC5=C(C=C4)C(=NC=N5)N MTWHDIHXYWJEFH-UHFFFAOYSA-N 0.000 description 1
- BOQZXGHEWNKPED-UHFFFAOYSA-N 1-[[5-(5-chlorothiophen-2-yl)-1,2-oxazol-3-yl]methyl]-4-(1h-pyrrolo[3,2-c]pyridin-2-ylmethyl)piperazin-2-one;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F.S1C(Cl)=CC=C1C1=CC(CN2C(CN(CC=3NC4=CC=NC=C4C=3)CC2)=O)=NO1 BOQZXGHEWNKPED-UHFFFAOYSA-N 0.000 description 1
- PLLLVRSRXFDRHN-UHFFFAOYSA-N 1h-pyrazole;thiophene Chemical compound C=1C=CSC=1.C=1C=NNC=1 PLLLVRSRXFDRHN-UHFFFAOYSA-N 0.000 description 1
- XWIYUCRMWCHYJR-UHFFFAOYSA-N 1h-pyrrolo[3,2-b]pyridine Chemical compound C1=CC=C2NC=CC2=N1 XWIYUCRMWCHYJR-UHFFFAOYSA-N 0.000 description 1
- BQGFWJWRQXSEOA-UHFFFAOYSA-N 4-[[5-(5-chlorothiophen-2-yl)-1,2-oxazol-3-yl]methyl]-1-(1h-pyrrolo[3,2-c]pyridin-2-ylmethyl)piperazin-2-one Chemical compound S1C(Cl)=CC=C1C1=CC(CN2CC(=O)N(CC=3NC4=CC=NC=C4C=3)CC2)=NO1 BQGFWJWRQXSEOA-UHFFFAOYSA-N 0.000 description 1
- NUAYNFYFICELME-UHFFFAOYSA-N 4-[[5-(5-chlorothiophen-2-yl)-1,3,4-thiadiazol-2-yl]methyl]-1-(1h-pyrrolo[3,2-c]pyridin-2-ylmethyl)piperazin-2-one;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F.S1C(Cl)=CC=C1C(S1)=NN=C1CN1CC(=O)N(CC=2NC3=CC=NC=C3C=2)CC1 NUAYNFYFICELME-UHFFFAOYSA-N 0.000 description 1
- LUEYUHCBBXWTQT-UHFFFAOYSA-N 4-phenyl-2h-triazole Chemical compound C1=NNN=C1C1=CC=CC=C1 LUEYUHCBBXWTQT-UHFFFAOYSA-N 0.000 description 1
- 206010002388 Angina unstable Diseases 0.000 description 1
- 0 CC(*)(C(*)(*)N(*)C(C1(*)*)O)N1IC Chemical compound CC(*)(C(*)(*)N(*)C(C1(*)*)O)N1IC 0.000 description 1
- 206010053567 Coagulopathies Diseases 0.000 description 1
- 206010051055 Deep vein thrombosis Diseases 0.000 description 1
- 208000005189 Embolism Diseases 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- SAKNAAUXGBNNMI-UHFFFAOYSA-N FC(C(=O)O)(F)F.FC(C(=O)O)(F)F.NC1=NC=NC2=CC(=CC=C12)CN1C(CN(CC1)CC1=NN=C(N1)C1=CC(=CC=C1)Cl)=O Chemical compound FC(C(=O)O)(F)F.FC(C(=O)O)(F)F.NC1=NC=NC2=CC(=CC=C12)CN1C(CN(CC1)CC1=NN=C(N1)C1=CC(=CC=C1)Cl)=O SAKNAAUXGBNNMI-UHFFFAOYSA-N 0.000 description 1
- UKQILUDBMLHVAA-UHFFFAOYSA-N FC(C(=O)O)(F)F.FC(C(=O)O)(F)F.NC1=NC=NC2=CC(=CC=C12)CN1C(CN(CC1)CC1=NN=C(N1)C1=CC=C(C=C1)Cl)=O Chemical compound FC(C(=O)O)(F)F.FC(C(=O)O)(F)F.NC1=NC=NC2=CC(=CC=C12)CN1C(CN(CC1)CC1=NN=C(N1)C1=CC=C(C=C1)Cl)=O UKQILUDBMLHVAA-UHFFFAOYSA-N 0.000 description 1
- PBHRUIUCEBANOM-UHFFFAOYSA-N FC(C(=O)O)(F)F.FC(C(=O)O)(F)F.NC1=NC=NC2=CC(=CC=C12)CN1C(CN(CC1)CC1=NN=C(N1)C=1SC(=CC1)Cl)=O Chemical compound FC(C(=O)O)(F)F.FC(C(=O)O)(F)F.NC1=NC=NC2=CC(=CC=C12)CN1C(CN(CC1)CC1=NN=C(N1)C=1SC(=CC1)Cl)=O PBHRUIUCEBANOM-UHFFFAOYSA-N 0.000 description 1
- FTPKMWKRAPBLAY-LTCKWSDVSA-N FC(C(=O)O)(F)F.FC(C(=O)O)(F)F.NC1=NC=NC2=CC(=CC=C12)CN1C([C@@H](N(CC1)CC1=NN=C(N1)C=1SC(=CC1)Cl)C)=O Chemical compound FC(C(=O)O)(F)F.FC(C(=O)O)(F)F.NC1=NC=NC2=CC(=CC=C12)CN1C([C@@H](N(CC1)CC1=NN=C(N1)C=1SC(=CC1)Cl)C)=O FTPKMWKRAPBLAY-LTCKWSDVSA-N 0.000 description 1
- FCDDOSASZFZHST-LTCKWSDVSA-N FC(C(=O)O)(F)F.FC(C(=O)O)(F)F.NC1=NC=NC2=CC(=CC=C12)CN1C([C@@H](N(CC1)CC=1SC(=NN1)C=1SC(=CC1)Cl)C)=O Chemical compound FC(C(=O)O)(F)F.FC(C(=O)O)(F)F.NC1=NC=NC2=CC(=CC=C12)CN1C([C@@H](N(CC1)CC=1SC(=NN1)C=1SC(=CC1)Cl)C)=O FCDDOSASZFZHST-LTCKWSDVSA-N 0.000 description 1
- XLIBNTXIKLQWEZ-UHFFFAOYSA-N FC(C(=O)O)(F)F.NC1=NC=NC2=CC(=CC=C12)CN1C(CN(CC1)CC1=NC=C(C=C1)C=1SC(=CC1)Cl)=O Chemical compound FC(C(=O)O)(F)F.NC1=NC=NC2=CC(=CC=C12)CN1C(CN(CC1)CC1=NC=C(C=C1)C=1SC(=CC1)Cl)=O XLIBNTXIKLQWEZ-UHFFFAOYSA-N 0.000 description 1
- DCBGTFAQYWJOSI-UHFFFAOYSA-N FC(C(=O)O)(F)F.NC1=NC=NC2=CC(=CC=C12)CN1C(CN(CC1)CC=1C=CC(=NC1)C=1SC(=CC1)Cl)=O Chemical compound FC(C(=O)O)(F)F.NC1=NC=NC2=CC(=CC=C12)CN1C(CN(CC1)CC=1C=CC(=NC1)C=1SC(=CC1)Cl)=O DCBGTFAQYWJOSI-UHFFFAOYSA-N 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 206010022562 Intermittent claudication Diseases 0.000 description 1
- 208000032382 Ischaemic stroke Diseases 0.000 description 1
- 150000001204 N-oxides Chemical class 0.000 description 1
- 208000031481 Pathologic Constriction Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 208000001435 Thromboembolism Diseases 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 208000007814 Unstable Angina Diseases 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 206010053648 Vascular occlusion Diseases 0.000 description 1
- 206010047249 Venous thrombosis Diseases 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 206010000891 acute myocardial infarction Diseases 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- PUJDIJCNWFYVJX-UHFFFAOYSA-N benzyl carbamate Chemical compound NC(=O)OCC1=CC=CC=C1 PUJDIJCNWFYVJX-UHFFFAOYSA-N 0.000 description 1
- 208000015294 blood coagulation disease Diseases 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- 125000004063 butyryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 238000007887 coronary angioplasty Methods 0.000 description 1
- 125000004093 cyano group Chemical group *C#N 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
- 125000002795 guanidino group Chemical group C(N)(=N)N* 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 201000004332 intermediate coronary syndrome Diseases 0.000 description 1
- 208000021156 intermittent vascular claudication Diseases 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 1
- ZMUADARPXLFDHP-UHFFFAOYSA-N nitrocarbamic acid Chemical class OC(=O)N[N+]([O-])=O ZMUADARPXLFDHP-UHFFFAOYSA-N 0.000 description 1
- 210000004789 organ system Anatomy 0.000 description 1
- GBXYTRIBFXZUBS-UHFFFAOYSA-N oxadiazole;thiophene Chemical compound C=1C=CSC=1.C1=CON=N1 GBXYTRIBFXZUBS-UHFFFAOYSA-N 0.000 description 1
- 125000001312 palmitoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- BSCCSDNZEIHXOK-UHFFFAOYSA-N phenyl carbamate Chemical compound NC(=O)OC1=CC=CC=C1 BSCCSDNZEIHXOK-UHFFFAOYSA-N 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 125000001325 propanoyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- KAVSMINTEBGDTI-UHFFFAOYSA-N pyridine;thiophene Chemical compound C=1C=CSC=1.C1=CC=NC=C1 KAVSMINTEBGDTI-UHFFFAOYSA-N 0.000 description 1
- CZAAKPFIWJXPQT-UHFFFAOYSA-N quinazolin-2-amine Chemical compound C1=CC=CC2=NC(N)=NC=C21 CZAAKPFIWJXPQT-UHFFFAOYSA-N 0.000 description 1
- 208000037803 restenosis Diseases 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 208000037804 stenosis Diseases 0.000 description 1
- 230000036262 stenosis Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- XBXCNNQPRYLIDE-UHFFFAOYSA-N tert-butylcarbamic acid Chemical compound CC(C)(C)NC(O)=O XBXCNNQPRYLIDE-UHFFFAOYSA-N 0.000 description 1
- JEJWGAXKVFYJDN-UHFFFAOYSA-N thiadiazole;thiophene Chemical compound C=1C=CSC=1.C1=CSN=N1 JEJWGAXKVFYJDN-UHFFFAOYSA-N 0.000 description 1
- HHNQDLUNMOECFS-UHFFFAOYSA-N thiophene;2h-triazole Chemical compound C=1C=CSC=1.C1=CNN=N1 HHNQDLUNMOECFS-UHFFFAOYSA-N 0.000 description 1
- 230000002537 thrombolytic effect Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 208000021331 vascular occlusion disease Diseases 0.000 description 1
- 210000005166 vasculature Anatomy 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US36319699A | 1999-07-28 | 1999-07-28 | |
| US09/363,196 | 1999-07-28 | ||
| PCT/IB2000/001156 WO2001007436A2 (en) | 1999-07-28 | 2000-07-26 | Substituted oxoazaheterocyclyl compounds |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2003508353A JP2003508353A (ja) | 2003-03-04 |
| JP2003508353A5 true JP2003508353A5 (https=) | 2007-09-06 |
| JP4829449B2 JP4829449B2 (ja) | 2011-12-07 |
Family
ID=23429232
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001512520A Expired - Fee Related JP4829449B2 (ja) | 1999-07-28 | 2000-07-26 | 置換オキソアザヘテロシクリル化合物 |
Country Status (25)
| Country | Link |
|---|---|
| EP (1) | EP1208097B1 (https=) |
| JP (1) | JP4829449B2 (https=) |
| KR (1) | KR20020087041A (https=) |
| CN (1) | CN1420882A (https=) |
| AT (1) | ATE423113T1 (https=) |
| AU (1) | AU773227B2 (https=) |
| BG (1) | BG106340A (https=) |
| BR (1) | BR0013179A (https=) |
| CA (1) | CA2382755A1 (https=) |
| CR (1) | CR6563A (https=) |
| CZ (1) | CZ2002323A3 (https=) |
| DE (1) | DE60041584D1 (https=) |
| EE (1) | EE200200045A (https=) |
| HK (1) | HK1054227A1 (https=) |
| HR (1) | HRP20020076A2 (https=) |
| HU (1) | HUP0203375A3 (https=) |
| IL (2) | IL147495A0 (https=) |
| MX (1) | MXPA02000888A (https=) |
| NO (1) | NO20020214L (https=) |
| PL (1) | PL354998A1 (https=) |
| RU (1) | RU2002105011A (https=) |
| SK (1) | SK1182002A3 (https=) |
| TR (1) | TR200200225T2 (https=) |
| WO (1) | WO2001007436A2 (https=) |
| ZA (1) | ZA200200543B (https=) |
Families Citing this family (95)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2001243441B2 (en) | 2000-03-21 | 2004-11-25 | Smithkline Beecham Corporation | Protease inhibitors |
| EP1322643A1 (en) * | 2000-09-29 | 2003-07-02 | Millennium Pharmaceuticals, Inc. | Piperazin-2-one amides as inhibitors of factor xa |
| EP1363705B9 (en) * | 2001-02-02 | 2012-11-07 | Bristol-Myers Squibb Company | Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives |
| GB0112836D0 (en) | 2001-05-25 | 2001-07-18 | Smithkline Beecham Plc | Medicaments |
| GB0114004D0 (en) | 2001-06-08 | 2001-08-01 | Glaxo Group Ltd | Chemical compounds |
| GB0114005D0 (en) | 2001-06-08 | 2001-08-01 | Glaxo Group Ltd | Chemical compounds |
| ATE319703T1 (de) | 2001-07-02 | 2006-03-15 | Piperidinverbindungen, die sich als modulatoren der chemokinrezeptoraktivität eignen | |
| GB0120461D0 (en) | 2001-08-22 | 2001-10-17 | Astrazeneca Ab | Novel compounds |
| US7763620B2 (en) | 2001-08-24 | 2010-07-27 | Yale University | Piperazinone compounds as anti-tumor and anti-cancer agents and methods of treatment |
| AU2007229363B2 (en) * | 2001-08-24 | 2009-06-04 | University Of South Florida | Piperazinone Compounds as Anti-Tumor and Anti-Cancer Agents and the Methods of Treatment |
| GB0122503D0 (en) | 2001-09-18 | 2001-11-07 | Astrazeneca Ab | Chemical compounds |
| EP1314733A1 (en) | 2001-11-22 | 2003-05-28 | Aventis Pharma Deutschland GmbH | Indole-2-carboxamides as factor Xa inhibitors |
| WO2003075853A2 (en) | 2002-03-08 | 2003-09-18 | Bristol-Myers Squibb Company | Cyclic derivatives as modulators of chemokine receptor activity |
| SE0200843D0 (sv) | 2002-03-19 | 2002-03-19 | Astrazeneca Ab | Chemical compounds |
| SE0200844D0 (sv) | 2002-03-19 | 2002-03-19 | Astrazeneca Ab | Chemical compounds |
| CA2484261A1 (en) | 2002-04-16 | 2003-10-23 | Teijin Limited | Piperidine derivatives having ccr3 antagonism |
| EP1505067A4 (en) | 2002-04-25 | 2006-06-21 | Teijin Ltd | 4,4-DISUBSTITUTED PIPERIDINE DERIVATIVES WITH CCR3 ANTAGONISM |
| AR040336A1 (es) | 2002-06-26 | 2005-03-30 | Glaxo Group Ltd | Compuesto de piperidina, uso del mismo para la fabricacion de un medicamento, composicion farmaceutica que lo comprende y procedimiento para preparar dicho compuesto |
| WO2004032930A1 (ja) * | 2002-10-11 | 2004-04-22 | Kowa Co., Ltd. | 癌の処置方法 |
| US7358268B2 (en) | 2002-12-04 | 2008-04-15 | Sanofi-Aventis Deutschland Gmbh | Imidazole derivatives as factor Xa inhibitors |
| US8729107B2 (en) | 2002-12-06 | 2014-05-20 | Purdue Research Foundation | Pyridines for treating injured mammalian nerve tissue |
| EP1567497B1 (en) * | 2002-12-06 | 2009-09-23 | Purdue Research Foundation | Pyridines for treating injured mammalian nerve tissue |
| US7429581B2 (en) | 2002-12-23 | 2008-09-30 | Sanofi-Aventis Deutschland Gmbh | Pyrazole-derivatives as factor Xa inhibitors |
| BRPI0408136A (pt) | 2003-03-07 | 2006-03-01 | Astellas Pharma Inc | derivados heterocìclicos contendo nitrogênio tendo estirila 2,6-dissubstituìda |
| SE0300957D0 (sv) | 2003-04-01 | 2003-04-01 | Astrazeneca Ab | Chemical compounds |
| US7741341B2 (en) | 2003-05-19 | 2010-06-22 | Sanofi-Aventis Deutschland Gmbh | Benzimidazole-derivatives as factor Xa inhibitors |
| US7223780B2 (en) | 2003-05-19 | 2007-05-29 | Sanofi-Aventis Deutschland Gmbh | Triazole-derivatives as blood clotting enzyme factor Xa inhibitors |
| EP1479675A1 (en) | 2003-05-19 | 2004-11-24 | Aventis Pharma Deutschland GmbH | Indazole-derivatives as factor Xa inhibitors |
| US7317027B2 (en) | 2003-05-19 | 2008-01-08 | Sanofi-Aventis Deutschland Gmbh | Azaindole-derivatives as factor Xa inhibitors |
| GB0315111D0 (en) * | 2003-06-27 | 2003-07-30 | Cancer Rec Tech Ltd | Substituted 5-membered ring compounds and their use |
| DE602004000260T2 (de) | 2003-07-22 | 2006-08-24 | Arena Pharmaceuticals, Inc., San Diego | Diaryl- und arylheteroarylharnstoffderivate als modulatoren des 5-ht2a-serotoninrezeptors, die sich zur prophylaxe und behandlung von damit im zusammenhang stehenden erkrankungen eignen |
| SE0303180D0 (sv) | 2003-11-26 | 2003-11-26 | Astrazeneca Ab | Novel compounds |
| TWI396686B (zh) | 2004-05-21 | 2013-05-21 | Takeda Pharmaceutical | 環狀醯胺衍生物、以及其製品和用法 |
| WO2006019497A2 (en) | 2004-06-17 | 2006-02-23 | Neurocrine Biosciences, Inc. | Sleep-inducing compounds and methods related thereto |
| GB0420831D0 (en) | 2004-09-17 | 2004-10-20 | Glaxo Group Ltd | Novel compounds |
| TWI385164B (zh) | 2005-02-17 | 2013-02-11 | Astellas Pharma Inc | Pyridyl non-aromatic nitrogen-containing heterocyclic-1-carboxylate derivatives (II) |
| WO2007008144A1 (en) * | 2005-07-08 | 2007-01-18 | Astrazeneca Ab | Heterocyclic sulfonamide derivatives as inhibitors of factor xa |
| WO2007008146A1 (en) * | 2005-07-08 | 2007-01-18 | Astrazeneca Ab | Heterocyclic sulfonamide derivatives as inhibitors of factor xa |
| JP2009501793A (ja) | 2005-07-21 | 2009-01-22 | アストラゼネカ・アクチエボラーグ | 新規ピペリジン誘導体 |
| EP1932839A4 (en) * | 2005-09-06 | 2014-09-10 | Shionogi & Co | INDOLECARBOXYLATE ACID DERIVATIVE HAVING ANTAGONIST EFFECT OF THE PGD2 RECEPTOR |
| CA2621261C (en) | 2005-09-22 | 2014-05-20 | Incyte Corporation | Azepine inhibitors of janus kinases |
| EP2407459A1 (en) | 2005-09-27 | 2012-01-18 | Shionogi & Co., Ltd. | Synthetic intermediate in the production of a sulfonamide derivative having PGD2 receptor antagonistic activity |
| UA96283C2 (uk) | 2005-12-23 | 2011-10-25 | Зіланд Фарма А/С | Модифіковані міметики лізину |
| EP2520567A3 (en) | 2006-02-23 | 2012-12-12 | Shionogi & Co., Ltd. | Nitrogen-containing heterocycle derivatives substituted with cyclic group |
| WO2007118130A2 (en) | 2006-04-06 | 2007-10-18 | Glaxo Group Limited | Antibacterial agents |
| US8017612B2 (en) | 2006-04-18 | 2011-09-13 | Japan Tobacco Inc. | Piperazine compound and use thereof as a HCV polymerase inhibitor |
| CN101528039A (zh) * | 2006-05-26 | 2009-09-09 | 路易斯维尔大学研究基金会公司 | 巨噬细胞迁移抑制因子拮抗剂及其应用方法 |
| EP1882688A1 (en) * | 2006-07-25 | 2008-01-30 | EPFL Ecole Polytechnique Fédérale de Lausanne | Labelling of fusion proteins with synthetic probes |
| TWI415845B (zh) | 2006-10-03 | 2013-11-21 | Arena Pharm Inc | 用於治療與５-ｈｔ2ａ血清素受體相關聯病症之作為５-ｈｔ2ａ血清素受體之調節劑的吡唑衍生物 |
| EP2074087A2 (en) | 2006-12-21 | 2009-07-01 | Wyeth | Synthesis of pyrrolidine compounds |
| KR101313804B1 (ko) * | 2007-03-20 | 2013-10-01 | 쿠리스 인코퍼레이션 | Ｈｓｐ９０ 억제제로서의 융합된 아미노 피리딘 |
| JP5393677B2 (ja) | 2007-08-15 | 2014-01-22 | アリーナ ファーマシューティカルズ， インコーポレイテッド | ５−ＨＴ２Ａセロトニン受容体に関連した障害の治療のための５−ＨＴ２Ａセロトニン受容体のモジュレーターとしてのイミダゾ［１，２−ａ］ピリジン誘導体 |
| US20110021538A1 (en) | 2008-04-02 | 2011-01-27 | Arena Pharmaceuticals, Inc. | Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor |
| TW200944526A (en) | 2008-04-22 | 2009-11-01 | Vitae Pharmaceuticals Inc | Carbamate and urea inhibitors of 11β-hydroxysteroid dehydrogenase 1 |
| CA2741731A1 (en) | 2008-10-28 | 2010-06-03 | Arena Pharmaceuticals, Inc. | Compositions of a 5-ht2a serotonin receptor modulator useful for the treatment of disorders related thereto |
| US9126946B2 (en) | 2008-10-28 | 2015-09-08 | Arena Pharmaceuticals, Inc. | Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)urea and crystalline forms related thereto |
| EP2480235A4 (en) | 2009-09-24 | 2013-05-08 | Univ Louisville Res Found | NEW IODO-PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF ILLNESSES AND SUFFERING IN CONNECTION WITH THE MACROPHAGE MIGRATION-INHIBITING FACTOR |
| US9155790B2 (en) | 2010-05-20 | 2015-10-13 | University of Lousiville Research Foundation, Inc. | Methods and compositions for modulating ocular damage |
| KR101251282B1 (ko) | 2010-10-18 | 2013-04-10 | 서울대학교산학협력단 | 프로스타글란딘 합성을 억제하는 설폰아미드 유도체 및 이를 포함하는 약학적 조성물 |
| CN102532159B (zh) * | 2010-11-12 | 2015-02-11 | 姚雪彪 | 动点马达蛋白CENP-E小分子抑制剂Syntelin |
| JP5951625B2 (ja) | 2010-11-24 | 2016-07-13 | ザ・トラスティーズ・オブ・コランビア・ユニバーシティー・イン・ザ・シティー・オブ・ニューヨークＴｈｅ Ｔｒｕｓｔｅｅｓ Ｏｆ Ｃｏｌｕｍｂｉａ Ｕｎｉｖｅｒｓｉｔｙ Ｉｎ Ｔｈｅ Ｃｉｔｙ Ｏｆ Ｎｅｗ Ｙｏｒｋ | 加齢性黄斑変性症およびシュタルガルト病の処置のための非レチノイドｒｂｐ４アンタゴニスト |
| PL395470A1 (pl) | 2011-06-29 | 2013-01-07 | Adamed Spólka Z Ograniczona Odpowiedzialnoscia | Sulfonamidowe pochodne amin alicyklicznych do leczenia chorób osrodkowego ukladu nerwowego |
| US9333202B2 (en) | 2012-05-01 | 2016-05-10 | The Trustees Of Columbia University In The City Of New York | Non-retinoid antagonists for treatment of age-related macular degeneration and stargardt disease |
| US9938291B2 (en) | 2013-03-14 | 2018-04-10 | The Trustess Of Columbia University In The City Of New York | N-alkyl-2-phenoxyethanamines, their preparation and use |
| WO2014152018A1 (en) | 2013-03-14 | 2014-09-25 | The Trustees Of Columbia University In The City Of New York | Octahydrocyclopentapyrroles, their preparation and use |
| US9944644B2 (en) | 2013-03-14 | 2018-04-17 | The Trustees Of Columbia University In The City Of New York | Octahydropyrrolopyrroles their preparation and use |
| US8669281B1 (en) | 2013-03-14 | 2014-03-11 | Alkermes Pharma Ireland Limited | Prodrugs of fumarates and their use in treating various diseases |
| EP3495357B1 (en) | 2013-03-14 | 2021-05-05 | The Trustees of Columbia University in the City of New York | 4-phenylpiperidines, their preparation and use |
| SG11201608943VA (en) | 2014-04-30 | 2016-11-29 | Univ Columbia | Substituted 4-phenylpiperidines, their preparaiton and use |
| CN106573893B (zh) | 2014-07-31 | 2020-06-09 | 巴斯夫欧洲公司 | 制备吡唑的方法 |
| CN104672235B (zh) * | 2015-02-14 | 2016-02-17 | 佛山市赛维斯医药科技有限公司 | 一类含双酰胺基和烷氧苯基结构的FXa抑制剂及其用途 |
| CN104650082B (zh) * | 2015-02-14 | 2016-06-01 | 佛山市赛维斯医药科技有限公司 | 一类凝血因子Xa抑制剂、制备方法及其用途 |
| CN104610259B (zh) * | 2015-02-14 | 2016-06-01 | 佛山市赛维斯医药科技有限公司 | 含酰胺和氮杂环结构的FXa抑制剂、制备方法及其用途 |
| CN104610260B (zh) * | 2015-02-14 | 2016-03-30 | 佛山市赛维斯医药科技有限公司 | 一类含酰胺和氮杂环结构的FXa抑制剂、制备方法及其用途 |
| CN104557928B (zh) * | 2015-02-14 | 2016-08-24 | 佛山市赛维斯医药科技有限公司 | 一种含二环酰胺结构凝血因子Xa抑制剂、其制备方法及其用途 |
| CN104610257B (zh) * | 2015-02-14 | 2016-06-01 | 佛山市赛维斯医药科技有限公司 | 一类含酰胺结构的FXa抑制剂、制备方法及其用途 |
| CN104650081B (zh) * | 2015-02-14 | 2016-06-01 | 佛山市赛维斯医药科技有限公司 | 凝血因子Xa抑制剂、制备方法及其用途 |
| CN104592227B (zh) * | 2015-02-14 | 2016-06-01 | 佛山市赛维斯医药科技有限公司 | 一类含酰胺和卤代苯结构的FXa抑制剂、制备方法及其用途 |
| CN104557930B (zh) * | 2015-02-14 | 2016-06-01 | 佛山市赛维斯医药科技有限公司 | 一种含二环酰胺结构凝血因子Xa抑制剂及其用途 |
| CN104557929B (zh) * | 2015-02-14 | 2016-06-01 | 佛山市赛维斯医药科技有限公司 | 一类含二环酰胺结构的凝血因子Xa抑制剂及其用途 |
| CN104610258B (zh) * | 2015-02-14 | 2016-03-30 | 佛山市赛维斯医药科技有限公司 | 一类含酰胺和甲氧苯结构的FXa抑制剂、制备方法及其用途 |
| CN104672236B (zh) * | 2015-02-14 | 2016-03-30 | 佛山市赛维斯医药科技有限公司 | 一类含双酰胺基和卤代苯结构的FXa抑制剂及其用途 |
| CN104557927B (zh) * | 2015-02-14 | 2016-06-01 | 佛山市赛维斯医药科技有限公司 | 一种含二环酰胺结构的凝血因子Xa抑制剂及其用途 |
| CA3187499A1 (en) | 2015-05-11 | 2016-11-17 | Eric George KLAUBER | Process for preparing 4-amino-pyridazines |
| US10022355B2 (en) | 2015-06-12 | 2018-07-17 | Axovant Sciences Gmbh | Diaryl and arylheteroaryl urea derivatives as modulators of the 5-HT2A serotonin receptor useful for the prophylaxis and treatment of REM sleep behavior disorder |
| CA2988572A1 (en) | 2015-06-26 | 2016-12-29 | Takeda Pharmaceutical Company Limited | 2,3-dihydro-4h-1,3-benzoxazin-4-one derivatives as modulators of cholinergic muscarinic m1 receptor |
| BR112018000728A2 (pt) | 2015-07-15 | 2018-09-04 | Axovant Sciences Gmbh | resumo método para a profilaxia e/ou tratamento de alucinações visuais em um sujeito com necessidade do mesmo |
| JP6787913B2 (ja) * | 2015-10-20 | 2020-11-18 | 武田薬品工業株式会社 | 複素環化合物 |
| WO2018082964A1 (en) | 2016-11-04 | 2018-05-11 | Basf Se | Process for the production of pyridazinyl-amides in a one-pot synthesis |
| EP3612527B1 (en) | 2017-04-18 | 2022-07-20 | Takeda Pharmaceutical Company Limited | Heterocyclic compounds useful as modulators of acetylcholine receptors |
| CN110709096B (zh) | 2017-05-05 | 2023-10-31 | 泽兰德制药公司 | 细胞间隙连接通讯调节剂及其在糖尿病性眼病治疗中的应用 |
| CN110054619A (zh) * | 2018-01-18 | 2019-07-26 | 西北农林科技大学 | 新型二酮哌嗪类组蛋白去乙酰化酶抑制剂 |
| US20210147371A1 (en) | 2018-04-10 | 2021-05-20 | Bayer Aktiengesellschaft | Oxadiazoline derivatives |
| CN109991355B (zh) * | 2019-04-12 | 2021-05-11 | 中国烟草总公司郑州烟草研究院 | 一种鉴定动物体内nab代谢产物的方法和评价nab在动物体内暴露风险的方法 |
| WO2022228387A1 (en) * | 2021-04-26 | 2022-11-03 | Fochon Biosciences, Ltd. | Compounds as parp inhibitors |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL310386A1 (en) * | 1993-02-22 | 1995-12-11 | Merck & Co Inc | Antagonists of factor i receptors |
| US5849736A (en) * | 1993-11-24 | 1998-12-15 | The Dupont Merck Pharmaceutical Company | Isoxazoline and isoxazole fibrinogen receptor antagonists |
| US5612353A (en) * | 1995-06-07 | 1997-03-18 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Substituted (sulfinic acid, sulfonic acid, sulfonylamino or sulfinylamino) N-[(aminoiminomethyl)phenylalkyl]-azaheterocyclylamide compounds |
| UA56197C2 (uk) * | 1996-11-08 | 2003-05-15 | Зенека Лімітед | Гетероциклічні похідні |
| NZ500354A (en) * | 1997-04-14 | 2001-11-30 | Cor Therapeutics Inc | Cyclic diaza compounds as selective factor Xa inhibitors for treating thrombotic related disorders |
| AU1692399A (en) * | 1997-12-26 | 1999-07-19 | Mochida Pharmaceutical Co., Ltd. | Aromatic compounds having cyclic amino or salts thereof |
| TR200002182T2 (tr) * | 1998-01-27 | 2000-12-21 | Aventis Pharmaceuticals Products Inc. | İkame edilmiş aksozaherosayklil faktör xa inhibitörleri |
| JP2000204081A (ja) * | 1998-02-05 | 2000-07-25 | Takeda Chem Ind Ltd | スルホンアミド誘導体、その製造法及び用途 |
| WO1999040075A1 (en) * | 1998-02-05 | 1999-08-12 | Takeda Chemical Industries, Ltd. | Sulfonamide derivatives, process for producing the same and utilization thereof |
| JP2003529531A (ja) * | 1998-11-25 | 2003-10-07 | アヴェンティス ファーマシューティカルズ インコーポレイテッド | 置換オキソアザへテロシクリルＸａ因子阻害剤 |
-
2000
- 2000-07-26 CN CN00810877A patent/CN1420882A/zh active Pending
- 2000-07-26 AT AT00951781T patent/ATE423113T1/de not_active IP Right Cessation
- 2000-07-26 EE EEP200200045A patent/EE200200045A/xx unknown
- 2000-07-26 CZ CZ2002323A patent/CZ2002323A3/cs unknown
- 2000-07-26 WO PCT/IB2000/001156 patent/WO2001007436A2/en not_active Ceased
- 2000-07-26 HK HK03106404.4A patent/HK1054227A1/zh unknown
- 2000-07-26 HU HU0203375A patent/HUP0203375A3/hu unknown
- 2000-07-26 EP EP00951781A patent/EP1208097B1/en not_active Expired - Lifetime
- 2000-07-26 TR TR2002/00225T patent/TR200200225T2/xx unknown
- 2000-07-26 CA CA002382755A patent/CA2382755A1/en not_active Abandoned
- 2000-07-26 PL PL00354998A patent/PL354998A1/xx not_active Application Discontinuation
- 2000-07-26 DE DE60041584T patent/DE60041584D1/de not_active Expired - Lifetime
- 2000-07-26 JP JP2001512520A patent/JP4829449B2/ja not_active Expired - Fee Related
- 2000-07-26 IL IL14749500A patent/IL147495A0/xx active IP Right Grant
- 2000-07-26 BR BR0013179-2A patent/BR0013179A/pt not_active IP Right Cessation
- 2000-07-26 RU RU2002105011/04A patent/RU2002105011A/ru unknown
- 2000-07-26 HR HR20020076A patent/HRP20020076A2/hr not_active Application Discontinuation
- 2000-07-26 KR KR1020027001192A patent/KR20020087041A/ko not_active Withdrawn
- 2000-07-26 MX MXPA02000888A patent/MXPA02000888A/es active IP Right Grant
- 2000-07-26 SK SK118-2002A patent/SK1182002A3/sk unknown
- 2000-07-26 AU AU64628/00A patent/AU773227B2/en not_active Ceased
-
2002
- 2002-01-06 IL IL147495A patent/IL147495A/en not_active IP Right Cessation
- 2002-01-15 NO NO20020214A patent/NO20020214L/no not_active Application Discontinuation
- 2002-01-22 ZA ZA200200543A patent/ZA200200543B/en unknown
- 2002-01-22 BG BG106340A patent/BG106340A/xx unknown
- 2002-01-25 CR CR6563A patent/CR6563A/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2003508353A5 (https=) | ||
| US8691861B2 (en) | Prodrugs of inhibitors of plasma kallikrein | |
| CN105358550B (zh) | 组蛋白脱乙酰基酶抑制剂 | |
| KR960701841A (ko) | 세포에서 Na'/H'교환 억제제로서 구아니딘 유도체(Guanidine derivatives as inhibitors of Na'/H' exchange in cells) | |
| IL165611A (en) | 1h - 1,2,4 - triazole - 3 - carboxamide derivatives and pharmaceutical composotions comprising them | |
| KR970706242A (ko) | 우레아 유도체 및 ACAT-억제제로서 그의 용도(Urea derivatives and their use as ACAT-inhibitors) | |
| CA2366857A1 (en) | Phthalazine derivatives for treating inflammatory diseases | |
| WO2003039529A1 (en) | Selective antibacterial agents | |
| CN109310679A (zh) | 包含组蛋白脱乙酰酶抑制剂的组合 | |
| CN101300229A (zh) | 作为胃酸分泌抑制剂的1-杂环基磺酰基、2-氨基甲基、5-(杂)芳基取代的1-h-吡咯衍生物 | |
| EP2512466A1 (en) | Prodrugs of inhibitors of plasma kallikrein | |
| JP2005533827A5 (https=) | ||
| RU2001120016A (ru) | Ароматические гетероциклические соединения, обладающие активностью в отношении ВИЧ-интегразы | |
| CA2496139A1 (en) | Benzimidazole derivatives | |
| JP2003513090A (ja) | Ｎ置換カルバモイルオキシアルキルアゾリウム誘導体 | |
| CA2529686A1 (en) | 2-acylaminothiazole derivative or salt thereof | |
| EP1213285A3 (en) | 4,5-dipheny-oxazole derivatives and their use as platelet aggregation inhibitors | |
| BRPI0715492A2 (pt) | uso de inibidores diretos de trombina | |
| CN102239152A (zh) | 新型酰胺衍生物及其作为药物的用途 | |
| KR920016422A (ko) | N-페닐카바메이트 화합물, 이의 제조방법 및 유해한 유기체를 방제하기 위한 살균 조성물 | |
| RU2374228C2 (ru) | Производные 4-фенилпиперидина в качестве ингибиторов ренина | |
| IL96390A (en) | Pharmaceutical compositions comprising n-alkylpiperazine-alkanamide derivatives for preventing or limiting reperfusion damage and some such novel compounds and their preparation | |
| FR2903405A1 (fr) | Composes a effet potentialisateur de l'activite de l'ethionamide et leurs applications | |
| CN101111236A (zh) | 血栓栓塞病的预防和治疗 | |
| JP2009543844A (ja) | 直接トロンビン阻害剤の新しい小児適応症 |